Quizartinib for Newly Diagnosed FLT3 -Internal Tandem Duplication–Negative AML
Journal of Clinical Oncology · 10.06.2026 · 44 (17) · 1648-1648
DOI: 10.1200/jco-25-02702 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.06.2026. Verfasst von Motoharu Shibusawa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Motoharu Shibusawa, MD, Sanaikai General Hospital, Saitama, Japan; and Tetsuya Tanimoto, MD, Medical Governance Research Institute, Tokyo, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Motoharu Shibusawa, MD, Sanaikai General Hospital, Saitama, Japan; and Tetsuya Tanimoto, MD, Medical Governance Research Institute, Tokyo, Japan.
ORCID-Profile: Motoharu Shibusawa, Tetsuya Tanimoto
Zitieren
APA
Shibusawa, M., & Tanimoto, T. (2026). Quizartinib for Newly Diagnosed FLT3 -Internal Tandem Duplication–Negative AML. Journal of Clinical Oncology, 44(17), 1648-1648. https://doi.org/10.1200/jco-25-02702
Vancouver
Shibusawa M, Tanimoto T. Quizartinib for Newly Diagnosed FLT3 -Internal Tandem Duplication–Negative AML. Journal of Clinical Oncology. 2026;44(17):1648-1648. doi:10.1200/jco-25-02702
BibTeX
@article{Shibusawa2026,
author = {Shibusawa, Motoharu and Tanimoto, Tetsuya},
title = {Quizartinib for Newly Diagnosed FLT3 -Internal Tandem Duplication–Negative AML},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {17},
pages = {1648--1648},
doi = {10.1200/jco-25-02702}
}
EUVIMED